Medicare, for insurers and Health-insurance
Digest more
The Trump administration has unveiled 15 new drugs selected for a Medicare drug price negotiation program that allows the federal government to haggle directly with drug manufacturers.
Lower prices from the third round of talks among Medicare and manufacturers will be announced in the fall but won’t go into effect until 2028.
The U.S. government on Tuesday named the 15 new drugs targeted for Medicare price negotiations for 2028, including Gilead Sciences' HIV drug Biktarvy and Pfizer's arthritis treatment Xeljanz.
The Trump administration on Tuesday announced the next round of prescription drugs up for Medicare price negotiations.
The CMS has proposed several key changes for 2027, to make sure Medicare "works better for the people it serves."
Too much of our national and personal resources are being used to pay for healthcare.
Jessica Tassan, Piper Sandler senior research analyst, joins 'The Exchange' to discuss Tassan's thoughts on UnitedHealth, the Medicare proposal change and much more.